Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 18 peer-reviewed journal articles Updated
Pulmonology

The Biology of Genetic ILD: How Mutations Affect Your Lungs

At a Glance

Genetic interstitial lung disease (ILD2) is caused by inherited DNA mutations that disrupt the production of lung surfactant. These mutations cause proteins to misfold, creating cellular stress that kills healthy lung cells and triggers permanent scarring (fibrosis) in the lungs.

To understand interstitial lung disease 2 (ILD2) and other genetic ILDs, we have to look at the “machinery” inside the lung cells. Unlike environmental ILD (caused by breathing in dust or mold) or autoimmune ILD (where the immune system attacks the body), genetic ILD is a “manufacturing error” inside the lung itself [1][2].

The Role of Surfactant

The lungs are lined with a substance called surfactant. Think of it as a thin, soapy film that prevents the tiny air sacs (alveoli) from collapsing and sticking together when you breathe out [2].

  • SFTPC & SFTPB: These genes provide the “recipe” for surfactant proteins C and B [2][3].
  • ABCA3: This gene acts like a “delivery truck,” transporting the lipids (fats) needed to build the surfactant film [4][5].

The Biology of “Misfolding” and Stress

In genetic ILD, the recipe is slightly wrong. This leads to a chain reaction of cellular stress:

  1. Protein Misfolding: In SFTPC mutations, the protein doesn’t fold into the correct shape. It becomes a tangled mess [6][7].
  2. ER Stress: These tangled proteins get stuck in the cell’s “factory floor,” known as the endoplasmic reticulum (ER). The cell realizes something is wrong and enters a state of high alarm called ER stress [6][8].
  3. The Unfolded Protein Response (UPR): The cell tries to fix the mess by activating its “cleanup crew” (the UPR). However, if the “factory” stays clogged, the cell eventually gives up and sends a signal to self-destruct (apoptosis) [9][8].
  4. Scarring (Fibrosis): As these vital lung cells (alveolar type 2 cells) die off, the body tries to heal the area by laying down tough, fibrous tissue. This scarring makes the lungs stiff and makes it harder for oxygen to pass into the blood [6][8][10].

Genetic vs. Other ILDs

Feature Genetic ILD (e.g., ILD2) Environmental/Autoimmune ILD
Root Cause Internal DNA mutation [2] External triggers or immune system error [1]
Cellular State High ER stress in lung cells [6] High levels of external inflammation/antibodies [11]
Family History Often present (familial) [12] Usually absent
Testing Confirmed by genetic sequencing [13] Confirmed by blood antibodies or exposure history [11]

Decoding Your Reports

When looking at your medical records, you may see specific terms that point toward a genetic cause:

  • Pathology Report: If a biopsy was done, the pathologist might see alveolar proteinosis (air sacs filled with protein) or a DIP-like pattern (desquamative interstitial pneumonia), which are common “red flags” for surfactant disorders [14][15].
  • Genetic Report: This report will list a specific variant. It will tell you if the change is pathogenic (known to cause disease) or a variant of uncertain significance (VUS) (a change that science is still studying) [16].

Completeness Checklist for Diagnosis

A definitive diagnostic report for genetic ILD should ideally include:

  • [ ] Specific Gene Name: (e.g., SFTPC, ABCA3, SFTPB, or NKX2-1) [2].
  • [ ] Variant Classification: Clear statement of whether the mutation is “Pathogenic” or “Likely Pathogenic” [16].
  • [ ] Inheritance Pattern: Whether it is autosomal dominant (one parent) or recessive (both parents) [2].
  • [ ] HRCT Findings: High-resolution CT results showing ground-glass hazy areas or cysts [17].
  • [ ] Extra-Pulmonary Review: A check for other signs, like thyroid or neurological issues, which can occur in some genetic syndromes (like NKX2-1 deficiency) [18].

Common questions in this guide

What causes genetic interstitial lung disease (ILD2)?
Genetic ILD is caused by inherited DNA mutations that act as manufacturing errors inside the lung cells. These mutations often affect the genes responsible for making surfactant, a vital substance that keeps lung air sacs open.
What happens to the lung cells in genetic ILD?
Mutations cause proteins in the lung cells to misfold, leading to a build-up of tangled proteins known as ER stress. The stressed cells eventually die, triggering the body to create tough scar tissue that makes breathing difficult.
How is genetic ILD different from other types of interstitial lung disease?
Unlike environmental or autoimmune lung diseases caused by outside triggers or an overactive immune system, genetic ILD originates from an internal DNA mutation. It is typically confirmed through genetic sequencing rather than exposure history or blood tests.
What terms should I look for in my ILD pathology report?
If you had a lung biopsy, red flags for a genetic surfactant disorder include alveolar proteinosis, where air sacs are filled with protein, or a DIP-like pattern.
What does a pathogenic variant mean on my genetic test?
A pathogenic variant means the specific DNA mutation found is known by scientists to cause disease. This helps doctors confirm that a genetic issue, rather than an environmental trigger, is responsible for your lung condition.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is the exact name of the genetic variant found (e.g., SFTPC I73T), and is it classified as 'pathogenic'?
  2. 2.Does the pathology or imaging report mention 'alveolar proteinosis' or 'DIP-like' patterns?
  3. 3.Does the mutation follow an 'autosomal dominant' or 'recessive' pattern of inheritance?
  4. 4.In my pathology report, are there specific signs of 'ER stress' or 'misfolded proteins' that confirm this genetic cause over an autoimmune one?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (18)
  1. 1

    Diagnosis and Pharmacologic Management of Fibrotic Interstitial Lung Disease.

    Berger K, Kaner RJ

    Life (Basel, Switzerland) 2023; (13(3)) doi:10.3390/life13030599.

    PMID: 36983755
  2. 2

    THERAPIES FOR NEONATAL DISEASES OF THE SURFACTANT SYSTEM.

    McCray PB

    Transactions of the American Clinical and Climatological Association 2025; (135()):119-129.

    PMID: 40771632
  3. 3

    Genetics of bronchopulmonary dysplasia: An update.

    Lavoie PM, Rayment JH

    Seminars in perinatology 2023; (47(6)):151811 doi:10.1016/j.semperi.2023.151811.

    PMID: 37775368
  4. 4

    Metabolic labelling of choline phospholipids probes ABCA3 transport in lamellar bodies.

    Li Y, Kinting S, Höppner S, et al.

    Biochimica et biophysica acta. Molecular and cell biology of lipids 2019; (1864(12)):158516 doi:10.1016/j.bbalip.2019.158516.

    PMID: 31473345
  5. 5

    Neonatal respiratory failure due to novel compound heterozygous mutations in the ABCA3 lipid transporter.

    Oltvai ZN, Smith EA, Wiens K, et al.

    Cold Spring Harbor molecular case studies 2020; (6(3)) doi:10.1101/mcs.a005074.

    PMID: 32532878
  6. 6

    An SFTPC BRICHOS mutant links epithelial ER stress and spontaneous lung fibrosis.

    Katzen J, Wagner BD, Venosa A, et al.

    JCI insight 2019; (4(6)).

    PMID: 30721158
  7. 7

    Cryptotanshinone is a candidate therapeutic agent for interstitial lung disease associated with a BRICHOS-domain mutation of SFTPC.

    Hosokawa M, Mikawa R, Hagiwara A, et al.

    iScience 2023; (26(10)):107731 doi:10.1016/j.isci.2023.107731.

    PMID: 37701577
  8. 8

    Disruption of proteostasis causes IRE1 mediated reprogramming of alveolar epithelial cells.

    Katzen J, Rodriguez L, Tomer Y, et al.

    Proceedings of the National Academy of Sciences of the United States of America 2022; (119(43)):e2123187119 doi:10.1073/pnas.2123187119.

    PMID: 36252035
  9. 9

    The unfolded protein response controls ER stress-induced apoptosis of lung epithelial cells through angiotensin generation.

    Nguyen H, Uhal BD

    American journal of physiology. Lung cellular and molecular physiology 2016; (311(5)):L846-L854 doi:10.1152/ajplung.00449.2015.

    PMID: 27638906
  10. 10

    Chronic Expression of a Clinical SFTPC Mutation Causes Murine Lung Fibrosis with Idiopathic Pulmonary Fibrosis Features.

    Rodriguez L, Tomer Y, Carson P, et al.

    American journal of respiratory cell and molecular biology 2023; (68(4)):358-365 doi:10.1165/rcmb.2022-0203MA.

    PMID: 36473455
  11. 11

    Connective Tissue Disease-Related Interstitial Lung Disease: Prevalence, Patterns, Predictors, Prognosis, and Treatment.

    Jeganathan N, Sathananthan M

    Lung 2020; (198(5)):735-759 doi:10.1007/s00408-020-00383-w.

    PMID: 32780179
  12. 12

    Genetic Familial Interstitial Lung Disease.

    Fernandez RJ, Kropski JA

    Clinics in chest medicine 2025; (46(4)):685-699 doi:10.1016/j.ccm.2025.07.008.

    PMID: 41110929
  13. 13

    An update on diagnosis and treatments of childhood interstitial lung diseases.

    Marczak H, Krenke K, Griese M, et al.

    Breathe (Sheffield, England) 2025; (21(2)):250004 doi:10.1183/20734735.0004-2025.

    PMID: 40365093
  14. 14

    Transbronchial Lung Cryobiopsy for Diagnosis of Pediatric Interstitial Lung Disease.

    Srikanta JT, Swarna S, Shylendra DS, Mehta R

    Indian pediatrics 2018; (55(6)):519-520.

    PMID: 29978822
  15. 15

    A disorder of surfactant metabolism without identified genetic mutations.

    Montella S, Vece TJ, Langston C, et al.

    Italian journal of pediatrics 2015; (41()):93 doi:10.1186/s13052-015-0198-3.

    PMID: 26606984
  16. 16

    Evaluating the Use of iPSC-Derived Models in Understanding the Pathogenesis of Childhood Interstitial Lung Disease.

    Jinson S, Shanthikumar S, Werder RB

    Pediatric pulmonology 2025; (60(5)):e71143 doi:10.1002/ppul.71143.

    PMID: 40432281
  17. 17

    A rare interstitial lung disease in young adulthood due to surfactant protein C gene mutation: Two case reports with brief literature review.

    Sengul Y, Gosche E, Hazelton T

    Radiology case reports 2025; (20(9)):4299-4303 doi:10.1016/j.radcr.2025.05.051.

    PMID: 40575365
  18. 18

    High-resolution computed tomography findings of thyroid transcription factor 1 deficiency (NKX2-1 mutations).

    LeMoine BD, Browne LP, Liptzin DR, et al.

    Pediatric radiology 2019; (49(7)):869-875 doi:10.1007/s00247-019-04388-3.

    PMID: 30927038

This page explains the cellular biology of genetic interstitial lung disease for educational purposes. Always consult a pulmonologist or genetic counselor to interpret your specific genetic and pathology reports.

Get notified when new evidence is published on Interstitial lung disease 2.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.